WO2024134380A1 - Compositions for ophthalmologic devices - Google Patents

Abstract

of the Invention The present invention relates eye care compositions, including contact lens packaging solutions containing at least one phosphate compound and a chelant in an amount effective to inhibit the growth of microorganisms without additional microbial growth inhibiting compounds. Methods of using the compositions of the present invention are also disclosed.

Description

Docket No. VTN6162WOPCT1 COMPOSITIONS FOR OPHTHALMOLOGIC DEVICES RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application Serial No. 63/476,537, filed December 21, 2022, U.S. Provisional Patent Application Serial No. 63/476,553, filed December 21, 2022; and U.S. Provisional Patent Application Serial No. 63/492,288, filed March 27, 2023; all of which is incorporated herein by reference in its entirety. FIELD OF TECHNOLOGY The present invention relates eye care compositions, including contact lens packaging solutions containing at least one phosphate compound and a chelant in an amount effective to inhibit the growth of microorganisms without additional microbial growth inhibiting compounds. Methods of using the compositions of the present invention are also disclosed. BACKGROUND OF THE INVENTION Contact lenses are generally provided to consumers as individually packaged products. The single unit containers which package such contact lenses typically use buffered saline as storage or packaging solutions. Such packaging solutions should provide for, at least in some cases, a short-term period – e.g., between solution preparation and sterilization of the end-staged packaged product - an environment that does not facilitate the growth of harmful or undesirable microorganisms. Such undesirable microorganisms include Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, Bacillus subtilis and Aspergillus brasiliensis. Moreover, the packaging solutions should be gentle to the eye since at least some of the packaging solution will, most likely, remain on a contact lens once it is removed from the packaging solution and placed directly on (i.e., by direct application to) the eye. 1    Docket No. VTN6162WOPCT1 The contact lens (or other ophthalmic device) packaging solution should also be compatible with the materials forming the contact lens (or other ophthalmic device) and the contact lens packaging. A challenge in preparing packaging solutions for ophthalmic devices is formulating solutions which do not negatively affect eye comfort or the solution’s compatibility with the material(s) forming the ophthalmic device. One important component of ophthalmic compositions, including packaging solutions, is the buffer incorporated, which helps to maintain the pH of the composition within an acceptable physiological range. Phosphates are known to be capable buffers, but, unfortunately, phosphates are also known promoters of microbial growth. The present inventors have found that by appropriately combining certain chelants and phosphate buffers, adequately buffered, bacteriostatic compositions (e.g., packaging solutions) can be achieved. DESCRIPTION OF FIGURES Figure 1 is reproduction of “Influence of concentration of phosphate on NaCl effect on phosphate pH” illustration from Robinson, H., W., The Influence of Neutral Salts on the pH of Phosphate Buffer Mixtures, J. Biol. Chem., LXXXII (3), 775-802, (1929)).  SUMMARY OF THE INVENTION The present invention relates to a sealed ophthalmologic product or kit, comprising: a) a composition for storing contact lenses as an admixture or mixture: i. a phosphate compound buffer; ii. at least one chelant in an amount effective to inhibit the growth of microorganisms in the composition; and 2    Docket No. VTN6162WOPCT1 iii. an ophthalmologically acceptable carrier comprising one or more tonicity agents at least one contact lens sealed in a container with the composition and b) a container comprising a sealed compartment comprising at least one contact lens in the presence of the composition. The present invention also relates to a method of inhibiting the growth of microorganisms in a composition from preparation of the composition to sterilization of the composition in sealed a container, comprising the steps of: a. mixing a composition comprising: i. a phosphate compound buffer; and ii. at least one chelant in an amount effective to inhibit the growth of microorganisms in the composition; b. storing the composition for the period of time during which time there is an inhibition of growth of microorganisms; c. placing the composition in a container; d. sealing the container of step c.; e. sterilizing the container of the d; optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. The present invention further relates to a method of packaging and sterilizing a composition in sealed a container, comprising the steps of: a. mixing a composition comprising: i. a phosphate compound buffer; and ii. at least one chelant in an amount effective to inhibit the growth of microorganisms in the composition; b. placing the composition in a container; 3    Docket No. VTN6162WOPCT1 c. sealing the container of step b.; d. sterilizing the container of the c. optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. The present invention also relates to methods of making and using the disclosed compositions. DETAILED DESCRIPTION OF THE INVENTION As indicated above, the present invention relates to compositions comprising one or more chelants and one or more phosphate compound as an ophthalmologically acceptable carrier. The compositions may be useful for storing or as a packaging solution for ophthalmic devices. Specifically, the present invention provides ophthalmic solutions comprising a transient microbial growth inhibiting compound that is bacteriostatic from the formulation of the composition through heat sterilization, such as autoclaving, but substantially or entirely neutralized during sterilization providing a non-preserved ophthalmic solution after sterilization. The present invention further provided hermetically sealed contact lens packages comprising a contact lens and an ophthalmic solution of the present invention. The compositions may be useful for direct application to the eyes for an eye care benefit such as relieving eye discomfort. The compositions and methods of the present invention can comprise, consist of, or consist essentially of the steps, essential elements and limitations of the invention described herein, as well any of the additional or optional ingredients, components, or limitations described herein. The term “comprising” (and its grammatical variations) as used herein is used in the inclusive sense of “having” or “including” and not in the exclusive sense of “consisting only of.” The terms “a” and “the” as used herein are understood to encompass the plural as well as the singular. 4    Docket No. VTN6162WOPCT1 Unless otherwise indicated, all documents cited are incorporated herein by reference. Furthermore, all documents incorporated herein by reference are only incorporated herein to the extent that they are not inconsistent with this specification. The citation of any document is not to be construed as an admission that it is prior art with response to the present invention. The present invention as disclosed herein may be practiced in the absence of any compound or element (or group of compounds or elements) which is not specifically disclosed herein. The term “pharmaceutically acceptable”, as used herein, means biologically tolerable, and otherwise biologically suitable for application or exposure to the eyes and surrounding tissues of the eyes without undue adverse effects such as toxicity, irritation, allergic response and the like. The term, “ophthalmically acceptable and/or compatible”, as used herein, means the composition or component(s) is pharmaceutically acceptable and is not or substantially is not, detrimental, negative, or harmful to any part of the eye (or surrounding tissues) or the other ingredients (including actives) in the composition itself.  The term “water soluble” as used herein, means that the components, either alone or in combination with other components, do not form precipitates or gel particles visible to the human eye at the concentrations selected and across the temperatures and pH regimes common for manufacturing, sterilizing and storing the ophthalmic solution. The term “cationic preservatives”, as used herein, means net positively charged compounds having antimicrobial properties and include, without limitation thereto, one or more of polymyxin B sulfate, quaternary ammonium compounds, poly(quaternary ammonium) compounds, benzalkonium chloride, cetylpridinium chloride, benzethonium chloride, cetyltrimethyl ammonium bromide, chlorhexidine, poly(hexamethylene biguanide), and mixtures thereof. Poly(quaternary ammonium) compounds are compounds that are positively charged surface active agents (i.e., cationic surfactants ) which act to compromise the cell walls and membranes , and examples include BUSAN 77, ONAMERM, MIRAPOLA15, IONENES A, 5    Docket No. VTN6162WOPCT1 POLYQUATERNIUM 11, POLYQUATER NIUM 7, BRADOSOL, AND POLYQUAT D-17- 1742. The term “effective to inhibit”, as used herein means an amount which causes an inhibition in the growth of microorganisms. The term “lidstock”, as used herein means, a flexible film or sheet which is heat sealed to the concave side of the plastic blister packaging to form a sealed cavity. Lidstock is generally multilayered and comprises a support layer and a peelable seal layer. The lidstock may further comprise additional layers including print layers, lamination layers, foil layers and combinations thereof and the like. The term “inhibition of growth of microorganisms” in the composition occurs where, and means that, there is a less than a 0.5 log, less than 0.3 log, less than 0.2 log, increase, or no increase in the count of any microorganism present in the composition after 1 day, 2 days, 3 days, 5 days, 7 days, 8 days, 10 days, 13 days, 14 days, 15 days, 20 days, 21 days or 22 days from date of preparation of the compositions of the present invention. The term "hydrogels" means polymeric networks that swell in water or aqueous solutions, typically absorbing at least 10 weight percent water. "Silicone hydrogels" are hydrogels that are made from at least one silicone-containing component with at least one hydrophilic component. Hydrophilic components may also include non-reactive polymers. The term “chlorous acid compounds” means compounds containing a chlorous acid or ophthalmically compatible salts thereof are ophthalmically. The chlorous acid compound may be an anhydride or a hydrate. The salts of chlorous acid may be a mono or a double salt. Examples of the chlorous acid compounds that can be avoided include (selected from or selected from the group consisting of), but are not limited to, chlorous acid; an alkali metal salt of chlorous acid including lithium chlorite, sodium chlorite, sodium chlorite trihydrate, or potassium chlorite and the like; an alkali earth metal salt of chlorous acid including magnesium chlorite, magnesium chlorite trihydrate, calcium chlorite, calcium chlorite trihydrate, barium chlorite, or barium chlorite dihydrate and the like; an earth metal salt of chlorous acid such as aluminum chlorite; a zinc-family salt of chlorous acid such as zinc chlorite dihydrate; a 6    Docket No. VTN6162WOPCT1 transitional metal salt of chlorous acid such as copper chlorite (II), copper chlorite (III), silver chlorite, nickel chlorite dihydrate or manganese chlorite; ammonium chlorite; a quaternary ammonium salt of chlorous acid such as tetramethylammonium chlorite; a quaternary phosphonium salt of chlorous acid such as (2,4-dinitrophenyl) triethylphosphonium chlorite; an amine salt of chlorous acid such as a methyl amine salt of chlorous acid, a tripropyl amine salt of chlorous acid, a hydrazine salt of chlorous acid, a pyridine salt of chlorous acid, a 4-methyl pyridine salt of chlorous acid, a 2,4-dimethyl pyridine salt of chlorous acid or a quinoline salt of chlorous acid; a double salt such as KClO2 ^NaClO2, Cu (ClO2)2 ^2KClO2 ^2H2O, Cu(ClO2)2 ^Mg (ClO₂)₂ ^8H₂O, or Cu(ClO₂)₂ ^Ba (ClO₂)₂ ^4H₂O and the like, but are not limited thereto. Sources of chlorous acid compounds such as stabilized oxychloro complex, (Purite, Bio-Cide International Inc., Ok, USA) and/or stabilized chlorite peroxide (SOC - Oxyd Tubilux.) may also be avoided. Salts of chlorous acid compounds include ophthalmically compatible salts including but not limited to, sodium chlorite, sodium chlorite trihydrate, or potassium chlorite and the like; an alkali earth metal salt of chlorous acid including magnesium chlorite, magnesium chlorite trihydrate, calcium chlorite, calcium chlorite trihydrate, or aluminum chlorite, ammonium chlorite; a quaternary ammonium salt of chlorous acid such as tetramethylammonium chlorite; a quaternary phosphonium salt of chlorous acid such as (2,4-dinitrophenyl) triethylphosphonium chlorite; an amine salt of chlorous acid such as a methyl amine salt of chlorous acid, a tripropyl amine salt of chlorous acid, a pyridine salt of chlorous acid, a 4-methyl pyridine salt of chlorous acid, a 2,4-dimethyl pyridine salt of chlorous acid or a quinoline salt of chlorous acid and mixtures of any of the above. “Chlorite compounds” include chlorite compounds and salts thereof, including (selected from or selected from the group consisting of), but are not limited to, water soluble alkali metal chlorites, water soluble alkaline metal chlorites and mixtures thereof. Specific examples of chlorite compounds that may be avoided include (selected from or selected from the group consisting of) potassium chlorite, sodium chlorite, calcium chlorite, magnesium chlorite and mixtures thereof. All percentages, parts and ratios are based upon the total weight of the composition of the present invention, unless otherwise specified. All such weights as they pertain to the listed 7    Docket No. VTN6162WOPCT1 ingredients are based on the active level and, therefore, do not include carriers or by-products that may be included in commercially available materials, unless otherwise specified. It has been surprisingly found that certain chelating agents, such as EDTA can provide bacteriostatic properties for inhibiting microbial growth in the compositions when used at concentrations between about 0.025 to about 0.075 wt% based upon the total weight of the composition upon formulation without the addition of other microbial growth inhibiting compounds such as chlorous acid compounds or peroxides. The bacteriostatic properties for inhibiting microbial growth may occur for and are in effect during a period of time, which may be from the preparation or manufacture of the compositions of the present invention up to the time of performing at least one sterilization method on the composition, which may be sterilization of the composition in a sealed package with at least one contact lens as described below. The period of time period may be up to two weeks, during which the solution is stored in a sealed container at ambient temperature.   By the phrase “period of time” as used in association with the bacteriostatic properties of the composition, it is meant up to or at least one day, two days, three days, four days, five days , six days, seven days eight days, ten days, twelve days, fourteen days, fifteen days, 18 days, 20 days, 21 days or 22 days from date of preparation of the compositions of the present invention. The period of time may be up two weeks, during which the solution is stored in a sealed container at ambient temperature. Buffers A variety of buffers may be used in the present invention, including one or more phosphate compound, sulfate compound, borate compound or organic acid buffer and mixtures thereof. The buffer has the buffer capacity and is present in an amount effective to buffer the composition to a pH of from about 5.0 to a pH of about 8.0, from about 5.5 to about 8.0, or a pH or a pH about 6.0 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 7.5, or a pH of about 7.0 to a pH of about 7.5, or a pH of greater than 7.2 (or about 7.2) to a pH of 7.5 (or about 7.5). In some embodiments the buffer may be include a borate buffer. Suitable borates include, but are not limited to, boric acid; pharmaceutically acceptable salts of boric acid, such as 8    Docket No. VTN6162WOPCT1 alkaline metal salts such as sodium borate, potassium borate; alkaline earth metal salts such as calcium borate, magnesium borate; transition metal salts such as manganese borate; and mixtures thereof. Specific examples of borate buffers include boric acid, sodium borate decahydrate and mixtures thereof. If present the borate compound can be present in the compositions at concentrations of from about 0.1%, preferably from about 0.2%, preferably from about 0.25%, w/v to less than or equal to 0.80% (or about 0.80%), preferably 0.7% (or about 0.7%), preferably 0.6% (or about 0.6%), preferably 0.5% (or about 0.5%), preferably 0.45% (or about 0.45%), preferably 0.4% (or about 0.4%), preferably 0.35% (or about 0.35%), preferably 0.3% (or about 0.3%), w/v, in each case, of the total composition. Phosphate Compound The compositions of the present invention, at the time of mixing, comprise a phosphate compound. As used herein, the term "phosphate" shall refer to phosphoric acid, anions and/or salts of phosphoric acid and other pharmaceutically acceptable phosphates, or combinations thereof. Suitable phosphates may be incorporated as one or more monobasic phosphates, dibasic phosphates and the like. Examples of phosphate compounds useful in the compositions are those selected from pharmaceutically acceptable phosphate salts of alkali and/or alkaline earth metals. The phosphate compound may include one or more of phytic acid (or salts thereof such as their potassium or sodium salts), sodium dibasic phosphate (Na2HPO4), sodium monobasic phosphate (NaH₂PO₄), and potassium monobasic phosphate (KH₂PO₄) salts. The phosphate compound may be present in an amount from 0.3wt% (or about 0.3%) to 0.9wt% (or about 0.9%), or from 0.4wt% (or about 0.4wt%) to 0.85wt% (or about 0.85wt%), or from 0.5wt% (or about 0.5wt%) to 0.8 wt% (or about 0.8wt%) or from 0.6 wt% (or about 0.6 wt%) to 0.75 wt% (or about 0.75wt%), based on the total composition upon formulation. In certain embodiments, the phosphate compound may be a combination of salts of the dibasic phosphate anion (HPO₄)^2- and salts of the monobasic phosphate anion (H₂PO₄)- where the concentration, prior to sterilization of the composition, of the dibasic phosphate anion (HPO4)^2- is from about 0.700% to about 0.900% and the concentration, prior to sterilization of the composition, the monobasic phosphate anion (H2PO4)- is from 0.500% to about 0.710%, by 9    Docket No. VTN6162WOPCT1 total weight of the composition when present as the sodium salt mono- and heptahydrates, respectively. The Organic Acid Buffer The compositions of the present invention comprise an organic acid buffer wherein the organic acid buffer is added to compositions of the present invention in its undissociated form or as the metal salt thereof. As used herein, the term “organic acid buffer” means an organic acid having two or more carboxylic acid groups. Preferred organic acid buffers for use in the compositions of the present invention have a or pK₂ value in the range of 6 (or about 6) to 8 (or about 8), preferably 6 (or about 6 ) to 7 ( or about 7). Suitable diprotic acids include maleic acid (pK2 = 6.5). Suitable hexaprotic acids include mellitic acid (pK6 = 7). Also useful herein is phytic acid (or salts thereof such as their potassium or sodium salts). Phytic acid has 12 replaceable protons, whereby six are strongly acidic (pKa approximately 1.5), three are weaker acidic (pKa between 5.7 and 7.6), and three are very weakly acidic (pKa >10.0) (Costello, A. J. R.; Glonek, T.; Myers, T. C., 1976:³¹P-nuclear magnetic resonance-pH titrations of myo-inositol hexaphosphate. Carbohydrate Research 46, 159–171). Mixtures of the above acids may also be used. The organic acid buffer may be selected from phytic acid, mellitic acid, maleic acid and salts thereof (such the sodium or potassium salts of the organic acids) and mixtures thereof. The organic acid buffer may be selected from maleic acid, its sodium or potassium salts and mixtures thereof. The organic acid buffer may be selected from mellitic acid, its sodium or potassium salts and mixtures thereof. The organic acid content (as sum of mono- and di-basic salts) of the present compositions is in the range of about 0.10% to about 0.4%, or about 0.18% to about 0.30%, or about 0.20% to about 0.28%, by weight the total weight of the composition upon formulation. The organic acid buffer may be a combination of salts of the dibasic organic acid anion (e.g., dibasic sodium maleate monohydrate) and salts of the monobasic organic acid anion (monobasic sodium maleate) where the concentration, prior to sterilization of the composition, of the dibasic organic acid anion is from about 0.1% to about 0.3% and the concentration, prior to sterilization of the composition, the monobasic organic acid anion is from 0.005% to about 10    Docket No. VTN6162WOPCT1 0.002%, by weight of the composition, when present as the metal (e.g., sodium) monohydrate in the case of the dibasic organic acid. The compositions of the present invention may also contain neutral salts (e.g., sodium chloride) to meet human physiologic osmolality requirements. It is well known that the presence of such neutral salts affects the pH of phosphate buffers. Increasing the concentration of neutral salts results in a negative shift in pH (i.e., resulting in more acidic environment). Without being limited by theory, it is believed that these departures from ideal behavior result from electrostatic interactions of the cations of the neutral and phosphate salts. This is illustrated in Figure 1 (reproduced from Robinson, H., W., The Influence of Neutral Salts on the pH of Phosphate Buffer Mixtures, J. Biol. Chem., LXXXII (3), 775-802, (1929)). 11    Docket No. VTN6162WOPCT1 The neutral salt (e.g., sodium chloride) is present at a concentration of from 0.62% (or about 0.62%) to 0.66% (or about 0.66%), or from 0.58% (or about 0.58%) to 0.75% (or about 0.75%, or from 0.10% (or about 0.10%) to 0.28% (or about 0.28%), or from 0.00% to 0.35% (or about 0.35%), by weight, of the composition of the present invention. Depending on the concentration of such neutral salt of the composition, the compositions of the present invention comprise monobasic phosphate anions (H₂PO4)- and dibasic phosphate anions (HPO4)^2- at following ratios: Neutral salt (e.g., sodium Monobasic phosphate anions (H₂PO₄)-/ Dibasic chloride) Concentration (wt%) phosphate anions (HPO₄)^2- Ratio 0.45% to 1.20% 0:1 to 0.45:1 0.50% to 0.90% 0.02:1 to 0.44:1 0.55% to 0.85% 0.10:1 to 0.34:1 0.60% to 0.80% 0.12:1 to 0.30:1 0.65% to 0.75% 0.14:1 to 0.24:1 Chelating Agent The compositions of the present invention comprise a chelating agent capable of providing the composition with bacteriostatic properties for inhibiting microbial growth during a period of time as described above. Suitable chelating agents include, ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof. The chelant may comprise EDTA. It has been surprisingly found that when the chelating agent, for example, EDTA is used at relatively high concentrations of about 0.02 to about 0.075 wt% EDTA, about 0.025 to about 0.075 wt% EDTA, or about 0.05 to about 0.075 wt% EDTA, based upon the total composition upon formulation. Other microbial growth inhibiting compounds do not need to be added to the composition to prevent microbial growth between formulating the composition and sterilization. The composition comprising the chelating agent may remain colorless or lightly colored, even after autoclaving, which can be determined visually or measured via known methods such as APHA color technique. The solution after autoclaving may have a APHA color value of less than about 180, or less than about 40. 12    Docket No. VTN6162WOPCT1 An Ophthalmologically Acceptable Carrier The compositions of the present invention comprise an ophthalmologically acceptable carrier. The ophthalmologically acceptable carrier may be water or an aqueous excipient solution. The term “aqueous” typically denotes a formulation wherein the excipient is at least about 50%, or at least about 75% or at least about 90% and up to about 95%, or about 99%, by weight, water. In certain embodiments, the compositions of the present invention are free of oils or oily substances (e.g., medium-chain triglycerides, castor oil, flaxseed oil and the like or mixtures thereof). The term “substantially free”, as used with respect to the oil or lipid compounds, means the present compositions contain less than 0.05%, or less than 0.025%, or less than 0.01%, or less than 0.005%, of such oils or oily components, by weight, based on the total composition. Hence, in certain embodiments, the compositions are not multiphasic compositions such as oil in water emulsions. The water is preferably distilled water. in certain embodiments, the carrier is free of C1-4 alcohols such as methanol, ethanol, propanol, isopropanol, butanol, and the like which can sting, irritate, or otherwise cause discomfort to the eye. The water may be present in the ophthalmologically acceptable carrier at concentrations of from about 96% to about 99.9%, or from about 98% to about 99.5%, or from about 99.0% to about 99.5%, by weight of the total composition. The ophthalmologically acceptable carrier may be present at concentrations of from about 96% to about 99.5%, or from about 98% to about 99.5%, or from about 98.5% to about 99.2%, by weight of the total composition. The compositions may be sterile, namely such that the absence of microbial contaminants in the product prior to release or use are statistically demonstrated to the degree necessary for such products. The compositions may be selected to have no or substantially no detrimental, negative, harmful effect on the contact lens being therein or on the eye (or on the region around the eye). 13    Docket No. VTN6162WOPCT1 The compositions according to the present invention are physiologically compatible with the eye and ophthalmic devices. Specifically, the composition should be “ophthalmologically safe” for use with an ophthalmic device such as a contact lens, meaning that a contact lens treated with the solution is generally suitable and safe for direct placement on or direct application to the eye without rinsing, that is, the solution is safe and comfortable for ophthalmic devices, of any frequency of application, wetted with the solution, including contact lenses of any wear frequency. An ophthalmologically safe composition has a tonicity and pH that is compatible with the eye and includes materials, and amounts thereof, that are ophthalmologically compatible and non-cytotoxic according to ISO standards and U.S. Food & Drug Administration (FDA) regulations. The compositions of the present invention may be adjusted with tonicity agents, to approximate the osmotic pressure of normal lacrimal fluids, which is equivalent to a 0.9 percent solution of sodium chloride. The compositions may be made substantially isotonic with physiological saline used alone or in combination with other tonicity agents such as dextrose, otherwise if simply blended with sterile water and made hypotonic or made hypertonic the ophthalmic devices such as contact lenses may lose their desirable optical parameters. Correspondingly, excess saline may result in the formation of a hypertonic composition, which will cause stinging, and eye irritation. The osmolality of the composition may be at least about 200 mOsm/kg to less than 500 mOsm/kg, or from about 200 to about 450 mOsm/kg, or from about 205 to about 380 mOsm/kg, or from about 210 to about 360 milliosmoles per kilogram (mOsm/kg), or from about 250 to about 350 mOsm/kg, or from about 270 to about 330 mOsm/kg, as measured using osmolality measurement method USP <785> (current as of November, 2022). The ophthalmic compositions will generally be formulated as sterile aqueous compositions or as non-sterile compositions which are subsequently sterilized. Examples of suitable tonicity adjusting agents include (selected from or selected from the group consisting of), but are not limited to, sodium, potassium, calcium, zinc and magnesium chloride, alkali metal halides, dextrose, and the like and mixtures thereof. These agents may be used individually in amounts ranging from about 0.01 to about 2.5%, from about 0.2 to about 1.5%, by weight of the total composition. 14    Docket No. VTN6162WOPCT1 The tonicity adjusting agent may be sodium chloride which can be incorporated at concentrations of from about 0.4 to about 0.9%, from about 0.4 to about 0.7%, or from about 0.5% to about 0.6% by weight of the total composition. The ophthalmologically acceptable carrier can contain one or more of the above- mentioned tonicity agents. The compositions of the present invention may have a pH of from about 5.0 to a pH of about 8.0, or a pH of from about 5.5 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 7.5, or a pH of about 7.0 to a pH of about 7.5, or a pH of about 7.2 to a pH of about 7.4. Compositions (as noted above) may have a pH matching the physiological pH of the human tissue to which the composition will contact or be directly applied. The pH of the ophthalmic composition may be adjusted using acids and bases, such as mineral acids, such as, but not limited to hydrochloric acid and bases such as sodium hydroxide. The compositions of the present invention are also useful as packaging solutions for packaging of ophthalmic devices and for storing such ophthalmic devices. The packaging solutions of the present invention may have a viscosity of less than about 5.2 cP at 25ºC. As used herein, "ophthalmic device" refers to an object that resides in or on the eye. These devices can provide optical correction, cosmetic enhancement, light blocking (including UV, HEV, visible light and combinations thereof) glare reduction, therapeutic effect, including preventing the progression of myopia, wound healing, delivery of drugs or neutraceuticals, diagnostic evaluation or monitoring, or any combination thereof. Ophthalmic devices include (selected from or selected from the group consisting of), but are not limited to, soft contact lenses, intraocular lenses, overlay lenses, ocular inserts, punctual plugs, and optical inserts. The ophthalmic device may be a contact lens. Contact lenses (or “contacts”) are placed directly on the surface of the eyes (e.g., placed on the film of tears that covers the surface of the eyes). Contact lenses include soft contact lens (e.g., conventional or silicone hydrogel), rigid contact lenses or hybrid contact lenses (e.g., with soft skirt or shell). Soft contact lenses may be formed from hydrogels. Contact lenses useful with the compositions can be manufactured employing various conventional techniques, to yield a shaped article having the desired posterior and anterior lens surfaces. Spincasting methods are disclosed in U.S. Pat. Nos.3,408,429 and 15    Docket No. VTN6162WOPCT1 3,660,545; static casting methods are disclosed in U.S. Pat. Nos.4,113,224, 4,197,266, and 5,271,875, each of which are herein incorporated by reference. Contact lens polymer materials useful for manufacturing suitable contact lenses include (selected from or selected from the group consisting of), but are not limited to, acofilcon A, alofilcon A, alphafilcon A, amifilcon A, aquafilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A, darfilcon A, deltafilcon A, delefilcon, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, fanfilcon A, focofilcon A, galyfilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon B, mafilcon A, mesifilcon A, methafilcon B, mipafilcon A, narafilcon A, narafilcon B, nelfilcon A, netrafilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, ofilcon A, omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, riofilcon A, samfilcon A, senofilcon A, senofilcon C, serafilcon, silafilcon A, siloxyfilcon A, somofilcon A, stenfilcon A, tefilcon A, tetrafilcon A, trifilcon A, vasurfilcon, verofilcon, vifilcon, and xylofilcon A. The contact lenses may be manufactured using polymer materials selected from (or selected from the group consisting of) comfilcon, etafilcon A, galyfilcon A, senofilcon A, senofilcon C, nelfilcon A, hilafilcon, samfilcon, serafilcon, tetrafilcon A, vasurfilcon, vifilcon, and polymacon. Conventional hydrogel contact lenses do not contain silicone containing components, and generally have higher water content, lower oxygen permeability and moduli than silicone hydrogels. Conventional hydrogels are prepared from monomeric mixtures predominantly containing hydrophilic monomers, such as 2-hydroxyethyl methacrylate (“HEMA”), N-vinyl pyrrolidone (“NVP”) or polyvinyl alcohols. United States Patents Nos.4,436,887, 4,495,313, 4,889,664, 5,006,622, 5,039,459, 5,236,969, 5,270,418, 5,298,533, 5,824,719, 6,420,453, 6,423,761, 6,767,979, 7,934,830, 8,138,290, and 8,389,597 disclose the formation of conventional hydrogels. Conventional hydrogels may be ionic or non-ionic and include (selected from or selected from the group consisting of) polymacon, etafilcon, genfilcon, hilafilcon, nesofilcon, nelfilcon, ocufilcon, omafilcon, lenefilcon and the like. The oxygen permeability of these conventional hydrogel materials is typically below 20-30 barrers. 16    Docket No. VTN6162WOPCT1 Silicon hydrogel formulations may include aquafilcon, balafilcon, samfilcon, lotrafilcon A and B, delefilcon, galyfilcon, senofilcon A, B and C, narafilcon, comfilcon, formofilcon, riofilcon, fanfilcon, stenfilcon, somofilcon, serafilcon, kalifilcon, verofilcon and the like. "Silicone hydrogels" refer to polymeric networks made from at least one hydrophilic component and at least one silicone-containing component. Examples of suitable families of hydrophilic components that may be present in the reactive mixture include (meth)acrylates, styrenes, vinyl ethers, (meth)acrylamides, N-vinyl lactams, N-vinyl amides, N-vinyl imides, N- vinyl ureas, O-vinyl carbamates, O-vinyl carbonates, other hydrophilic vinyl compounds, and mixtures thereof. Non-limiting examples of hydrophilic components include N,N-dimethyl acrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), N-vinyl pyrrolidone (NVP), N-vinyl acetamide (NVA), N-vinyl-N-methylacetamide (VMA), and mixtures thereof. Silicone- containing components are well known and have been extensively described in the patent literature. For instance, the silicone-containing component may comprise at least one polymerizable group (e.g., a (meth)acrylate, a styryl, a vinyl ether, a (meth)acrylamide, an N- vinyl lactam, an N-vinylamide, an O-vinylcarbamate, an O-vinylcarbonate, a vinyl group, or mixtures of the foregoing), at least one siloxane group, and one or more linking groups (which may be a bond) connecting the polymerizable group(s) to the siloxane group(s). The silicone- containing components may, for instance, contain from 1 to 220 siloxane repeat units, from 3 to 100, from 3 to 40, or from 3 to 20 siloxane repeat units. The silicone-containing component may also contain at least one fluorine atom. The ophthalmic devices may also include a polymeric wetting agent, which may be incorporated into the ophthalmic device in a number of ways including, but not limited to, as a non-reactive polymer and become entrapped in the hydrogel upon polymerization forming a semi-interpenetrating network, may be polymerized (with or without crosslinking) in a preformed contact lens to form a fully or semi-interpenetrating network respectively or may be added to the packaging solution of the present invention and up-taken into the contact lens during sterilization Examples of these are disclosed in 6,367,929, US10,935,695, US8,053,539, US10,371,865, US10,370,476, US6,822,016, US7,431,152, US7,841,716 and US7,262,232. Alternatively, the polymeric wetting agent may be polymerizable, for example as polyamide macromers or prepolymers, and in this case, are covalently incorporated into the 17    Docket No. VTN6162WOPCT1 silicone hydrogels. Mixtures of polymerizable and non-polymerizable polyamides may also be used. Examples of suitable wetting agents include cyclic and linear polyamides, and specific examples include polyvinylpyrrolidone (PVP), polyvinylmethyacetamide (PVMA), polydimethylacrylamide (PDMA), polyvinylacetamide (PNVA), poly(hydroxyethyl(meth)acrylamide), polyacrylamide, and copolymers and mixtures thereof. The polymeric wetting agent may be PVP, a mixture of PVP (e.g., PVP K90) and PVMA (e.g., having a Mw of about 570 KDa). When the polyamides are incorporated into the reactive monomer mixture they may have a weight average molecular weight of at least 100,000 daltons; greater than about 150,000; between about 150,000 to about 2,000,000 daltons; between about 300,000 to about 1,800,000 daltons. Higher molecular weight polyamides may be used if they are compatible with the reactive monomer mixture. The hydrogel or silicone hydrogel formulations may also contain additional components such as, but not limited to, diluents, initiators, light absorbing compounds, including UV, HEV or visible light absorbers, photochromic compounds, pharmaceuticals, nutraceuticals, antimicrobial substances, tints, pigments, copolymerizable dyes, nonpolymerizable dyes, release agents, and combinations thereof. Silicone hydrogel lenses may contain a coating, and the coating may be the same or different material from the substrate. Silicone hydrogels may have moduli in the range of 60-200, 60-150 or 80 -130 psi, water contents in the range of 20 to 60% and contact angles less than about 100˚, less than about 80˚, and less than about 60˚. Examples of silicone hydrogels include acquafilcon, asmofilcon, balafilcon, comfilcon, delefilcon, enfilcon, fanfilcon, formofilcon, galyfilcon, lotrafilcon, lehfilcon, kalifilcon, narafilcon, riofilcon, samfilcon, senofilcon, serafilcon, somofilcon, stenfilcon, unifilcon, and verofilcon including all of their variants, as well as silicone hydrogels as prepared in US Patent Nos.4,659,782, 4,659,783, 5,244,981, 5,314,960, 5,331,067, 5,371,147, 5,998,498, 6,087,415, 5,760,100, 5,776,999, 5,789,461, 5,849,811, 5,965,631, 6,367,929, 6,822,016, 6,867,245, 6,943,203, 7,247,692, 7,249,848, 7,553,880, 7,666,921, 7,786,185, 18    Docket No. VTN6162WOPCT1 7,956,131, 8,022,158, 8,273,802, 8,399,538, 8,470,906, 8,450,387, 8,487,058, 8,507,577, 8,637,621, 8,703,891, 8,937,110, 8,937,111, 8,940,812, 9,056,878, 9,057,821, 9,125,808, 9,140,825, 9156,934, 9,170,349, 9,244,196, 9,244,197, 9,260,544, 9,297,928, 9,297,929 as well as WO 03/22321, WO 2008/061992, US 2010/0048847, US2023/0037781, US2021/0109255, US10,935,695, US8,053,539, US10,371,865, and US10,370,476. These patents are hereby incorporated by reference in their entireties. The contact lens polymer material may be a silicone hydrogel polymer. The silicone hydrogel may be selected from (or selected from the group consisting of) acquafilcon, asmofilcon, balafilcon A, comfilcon, delefilcon, enfilcon, fanfilcon, galyfilcon, lotrafilcon, senofilcon, samfilcon, somofilcon, stenfilcon, riofilcon, lehfilcon, kalifilcon, serafilcon, unifilcon, verofilcon. The compositions may also be useful for direct application to eye as a wetting or rewetting eye drop for providing relief to eye discomfort (e.g., burning sensations relating to the eye or general eye irritation). Once manufactured, the compositions of the present invention are not further mixed with another or separate composition(s) prior to direct application to the eye or for storing of (or as packaging solution for) ophthalmic devices (e.g., contacts) – namely the compositions of the present invention (or products thereof) are not in the form of 2- or multi- compositions or products. The compositions described herein may, at the time of mixing, be free of or substantially free of boric acid, borates, non-chlorous acid preservatives (especially cationic preservatives), peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, glycerin, polyoxyethylene-castor oil and/or derivatives thereof. As used herein, the term "borate" refers to salts of boric acid and other pharmaceutically acceptable borates, or combinations thereof. Suitable borates include, but are not limited to, boric acid; pharmaceutically acceptable salts, such as alkaline metal salts such as sodium borate, potassium borate; alkaline earth metal salts such as calcium borate, magnesium borate; transition metal salts such as manganese borate; and mixtures thereof. However, recent EU member state proposals for limiting the concentration boric acid and/or borates in eye care formulations 19    Docket No. VTN6162WOPCT1 reduces the desirability of incorporating such compounds in the compositions of the present invention. (See CLH REPORT FOR BORIC ACID AND BORATES, Proposal for Harmonised Classification and Labelling Based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI, Part 2, Swedish Chemicals Agency Nov.2, 2018.) The term “non-chlorous acid preservative” means compounds, which are not chlorous acid compounds, but have antimicrobial properties. Examples of specific preservatives include, but are not limited to, 4-chlorocresol, 4-chloroxylenol, benzalkonium, benzalkonium chloride (BAK), benzoic acid, benzyl alcohol, chlorhexidine, chlorobutanol, imidurea, m-cresol, methylparaben, phenols 0.5%, phenoxyethanol, sorbate, propionic acid, propylparaben, sodium benzoate, sorbic acid, thimerosol, polyquaternium compounds (such as polyquarternium-42 and polyquarternium-1), biguanide compounds ( e.g., polyhexamethylene biguanide or polyaminopropyl biguanide). Non-chlorous acid preservatives, especially cationic preservatives, can be irritating to eye and/or cause allergic reactions, undesirably affecting consumers’ use of the eye care compositions or contact lens which contain (on its surface) such non-chlorous acid preservative due to the storage of the contact lens with such compounds. For example, see: ^ Baudouin See C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res.2010 Jul;29(4):312-34 (concluding that cationic preservative “BAK may cause or enhance harmful consequences on the eye structures of the anterior segment, the tear film, cornea, conjunctiva, and even trabecular meshwork.”) ^ Lakshman Subbaraman, Contact lens material properties that influence preservative uptake, Contact Lens Update, October 1, 2013 (https://contactlensupdate.com/2013/10/01/contact-lens-material-properties-that- influence-preservative-uptake/) (Noting particular concern when contact lens are involved - “when a lens care product interacts with a contact lens, components such as preservatives present in the solution will be taken up by the lens material. When these preservatives are released from contact lenses into the eye during lens wear, it can have a significant impact on comfort during lens wear.”) 20    Docket No. VTN6162WOPCT1 As used herein, the term “sources of peroxides”, means a compound or material that releases (or can release peroxide or hydrogen peroxide) in aqueous solution and includes, but are not limited to, barium peroxide, sodium peroxide, zinc peroxide, magnesium peroxide, calcium peroxide, strontium peroxide, lithium peroxide, butanone peroxide, cyclohexanone peroxide, benzoyl peroxide, urea hydrogen peroxide (carbamide peroxide, carbamide perhydrate, or percarbamide), percarbonates such as calcium percarbonate or magnesium percarbonate, tert- butylhydroperoxide, perborate salts such as sodium perborate, peroxy acids such as methyl ethyl ketone peroxide, mixtures thereof and derivatives. Peroxides (e.g., hydrogen peroxide) and/or sources of peroxides can be harsh and irritating to eye and can undesirably affect consumers’ use of contact lens which contain (on its surface) the peroxides (e.g., hydrogen peroxide) and/or sources of peroxides due to the storage of the contact lens with such compounds. As used herein, the term "persulfates", means persulfate anions or salts of such persulfates and other pharmaceutically acceptable persulfates, or combinations thereof. Suitable persulfates include, but are not limited to, sodium peroxymonosulfate, potassium peroxymonosulfate, sodium persulfate , ammonium persulfate potassium persulfate and mixtures thereof. Persulfates can be harsh and irritating to eye and can undesirably affect consumers’ use of contact lens which contain (on its surface) the persulfates due to the storage of the contact lens with such compounds. Humectants and/or demulcents such as carboxy vinyl polymers (e.g., carbomers), natural gums (e.g., guar gum, gum tragacanth), glycerin, polyoxyethylene-castor oil and/or derivatives thereof are well known thickening agents which, when present on surface of contact lenses, can undesirably affect consumers’ vision through contact lens, causing blurring or otherwise reducing vision clarity by either interacting with the surface of the contact lens or slowly diffusing from the tear fluid trapped between the eye-facing side of the contact lens and the corneal surface. Though the latter effect is generally temporary, dissipating within several minutes post insertion with trapped fluid being cleared by repetitive blinking, such visual impairing effects may be undesirable. The term “substantially free” as related to compounds selected from boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers (e.g., carbomers), natural gums (e.g., guar gum, gum 21    Docket No. VTN6162WOPCT1 tragacanth)glycerin, polyoxyethylene-castor oil and/or derivatives means that such compounds are present in the compositions of the present invention as impurities which are not intentionally added or are at a concentration of less than 2% (or about 2%), or less than 1.5% (or about 1.5%), or less than 1% (or about 1%), or less than 0.5% (or about 0.5%), or less than 0.1% (or about 0.1%), or less than 0.05% (or about 0.05%), or less than 0.01% (or about 0.01%), or less than 0.005% (or about 0.005%) by weight of the total composition. In certain embodiments, the compositions of the present invention may be free of such compounds. As mentioned above, contact lenses can be immersed in a composition of the present invention and stored in a suitable packaging container, in certain embodiments, a packaging container for single contact lens unit. Generally, a packaging container for the storage of a contact lens includes at least a sealing layer sealing the container containing an unused contact lens immersed in the composition of the present invention. The sealed container may be hermetically sealed packaging container and may have any form that creates a sealed space to contain the composition and contact lens. The hermetically sealed packaging container may have any suitable form include sealed packets formed from two sheets of plastic, metal or multilayer structures or a blister pack in which a base with a concave well containing a contact lens is covered by a metal, plastic or laminate sheet adapted for peeling in order to open the blister-pack. The sealed container may be formed from any suitable, generally inert packaging material providing a reasonable degree of protection to the lens. The packaging material may be formed of plastic material such as polypropylene, polysulfone (PSU), polyethersulfone (PESU), polycarbonate (PC), polyetherimide (PEI), polyamides, including nylons, polyolefins including polypropylene, polymethylpentene, (PMP), and olefin co-polymers, including COPs (Cyclic Olefin Polymer) and COCs,(Cyclic Olefin Co-polymers), acrylics, rubbers, urethanes, fluorocarbons, polyoxymethylene, polyvinylchloride (PVC), polyphenylsulfide (PPS), polycarbonate copolymers, polyvinylidene fluoride (PVDF), and the like and copolymers and blends of the foregoing. Blends include polybutylene terephthalate polyester blends, including PBT and PC blends, PC/polyester blends, and polypropylene blended with COPs or COCs. In one embodiment the plastic material may be selected from polypropylene, COPs (Cyclic Olefin Polymer) and COCs, (Cyclic Olefin Co-polymers) and blends thereof. 22    Docket No. VTN6162WOPCT1 Except for the specific demulcents mentioned above, any water soluble, demulcent (or demulcent like – e.g., having demulcent properties such as viscosity increasing capabilities) polymer may also be employed in the composition of this invention provided that it has no (or no substantial) detrimental effect on the contact lens being stored or on the wearer of the contact lens (e.g., blurring or otherwise reducing vision clarity) at the concentrations used in the composition of the present invention or on the eye (or on the region around the eye). Particularly useful components are those, which are water soluble, for example, soluble at the concentrations used in the presently useful liquid aqueous media. Suitable water soluble demulcent polymers include, but are not limited to, demulcent polymers, such as block copolymer surfactants (e.g., block copolymers of polyethyleneoxide (PEO) and polypropyleneoxide (PPO)); polyvinyl alcohol, polyvinyl pyrrolidone; polyacrylic acid; polyethers such as polyethylene glycols (e.g., polyethylene glycol 300, polyethylene glycol 400) and polyethylene oxides; hyaluronic acid, and hyaluronic acid derivatives such as sodium hyaluronate) ; chitosan; polysorbates such as polysorbate 80, polysorbate 60 and polysorbate 40); dextrans such as dextran 70; cellulosic derivatives such as carboxy methyl cellulose methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and methyl ethyl cellulose; acyclic polyamides such as those having a weight average molecular weight of 2,500 to 1,800,000 Daltons as disclosed in US7,786,185 herein incorporated by reference in its entirety; salts of any of the above and mixtures of any of the above. The block copolymers of PEO and PPO include poloxamers and poloxamines, including those disclosed in US6,440,366, herein incorporated by reference in its entirety. In certain embodiments, the water-soluble demulcent polymer is selected from polyvinyl pyrrolidone, methyl ethyl cellulose, polyvinyl alcohol, polymethacrylic acid, carboxymethyl cellulose, propylene glycol, 1,3-propanediol, polyethylene glycols, and mixtures thereof. Water-soluble demulcent polymers may have molecular weights in excess of 100,000. When propylene glycol and/or 1,3-propanediol are used as water-soluble demulcent polymers, they may have molecular weights lower than 100,000. When any water-soluble polymer is used in the packaging solutions of the present invention, it may be included and present in amounts up to about 0.5, 1 or 2 weight %, or between about 0.001 and about 2%, or between about 0.005 and about 1 weight %, or between 23    Docket No. VTN6162WOPCT1 about 0.01 and about 0.5 weight %, or between about 100 ppm by weight and about 0.5 weight %, all based upon the weight of total composition. When any water soluble polymer is used in the direct application eye care formulation, such as an eye drop of the present invention, it may be included and present in amounts up to about 2, 5 or 10 weight %, or between about 0.001 and about 10 weight %, or between about 0.005 and about 2 weight % , or between about 0.01 and about 0.5 weight %, or between about 100 ppm by weight and about 2 weight%, all based upon the weight of total composition. Without being limited by theory, it is believed that the water-soluble demulcent polymer aids in preventing the ophthalmic device from sticking to the packaging container and may enhance the initial (and/or extended) comfort of the contact lens, packaged in the composition, when placed on the eye after removal from the packaging container. The demulcent polymer may be a cellulosic derivative. The cellulosic derivative may be present at concentrations of from about 0.002% to about 0.01%, or from about 0.004% to about 0.006%, by weight of the total composition of the present invention. Various other materials may be included with the compositions described herein. In the case of compositions of the present invention for direct application to the eye, surfactants may be included. Surfactants suitable for such use include, but are not limited to, ionic and nonionic surfactants (though nonionic surfactants are preferred), RLM 100, POE 20 cetylstearyl ethers such as Procol® CS20, poloxamer block copolymers (such as Pluronic® F68, and block copolymers such as poly(oxyethylene)-poly(oxybutylene) compounds set forth in US2008/0138310 (which publication is herein incorporated by reference). The poly(oxyethylene)-poly(oxybutylene) block copolymer may have the formula (EO)m(BO)n, wherein EO is oxyethylene and BO is oxybutylene, and wherein m is an integer having an average value of 10 to 1000 and n is an integer having an average value of 5 to 1000, as disclosed in US8,318,144; m may also be 10 and n may be 5. Surfactants may be present at concentrations of from about 0.01 to about 3%, or from about 0.01 to about 1%, or from about 0.02 to about 0.5%, or from about 0.02 to about 0.1%, by weight of the total composition of the present invention. It should be appreciated that some of 24    Docket No. VTN6162WOPCT1 the components may perform more than one function, for example, some demulcents may also function as surfactants (e.g., PEO-PPO and PEO-PBO block copolymers). If desired, one or more additional components may be, optionally, included in the composition. Such optional component(s) are chosen to impart or provide at least one beneficial or desired property to the composition. Such additional, but optional, components may be selected from components that are conventionally used in ophthalmic device care compositions Examples of such optional components include (or, are selected from or selected from the group consisting of) cleaning agents (for example in direct application eye drops or cleaning [or eye care solution]), wetting agents, nutrient agents, therapeutic agent, sequestering agents, viscosity builders, contact lens conditioning agents, antioxidants, and the like and mixtures thereof. These optional components may each be included in the compositions in an amount effective to impart or provide the beneficial or desired property to the compositions such the beneficial or desired property is noticeable to the user. For example, such optional components may be included in the compositions in amounts similar to the amounts of such components used in other eye or ophthalmic device care compositions products. In one embodiment the ophthalmic solution comprises a phosphate buffer, about 0.02 to about 0.075 wt% EDTA, about 0.025 to about 0.075 wt% EDTA or about 0.05 to about 0.075 wt% EDTA, about 0.005 to about 0.01 wt% methyl ethyl cellulose and optionally up to about 1, about 1.5 or about 2 wt% PVP K30, K60 or K90, or K60, all by weight of the ophthalmic solution as formulated, prior to autoclaving. The ranges may be combined in any permutation. The ophthalmic solution may be used as a packaging solution with contact lenses, including silicone hydrogel contact lenses, comprising PVP. All components in the ophthalmic solution of the present invention should be water- soluble. One or more therapeutic agent may also be incorporated into the ophthalmic solution. A wide variety of therapeutic agents may be used, so long as the selected active agent is inert in the presence of chelant generally. Suitable therapeutic agents include those that treat or target any part of the ocular environment, including the anterior and posterior sections of the eye and include pharmaceutical agents, vitamins, nutraceuticals combinations thereof and the like. 25    Docket No. VTN6162WOPCT1 Suitable classes of active agents include antihistamines, antibiotics, glaucoma medication, carbonic anhydrase inhibitors, anti-viral agents, anti-inflammatory agents, non- steroid anti-inflammatory drugs, antifungal drugs, anesthetic agents, miotics, mydriatics, immunosuppressive agents, antiparasitic drugs, anti-protozoal drugs, combinations thereof and the like. When active agents are included, they are included in an amount sufficient to produce the desired therapeutic result (a “therapeutically effective amount”). Useful optional sequestering agents include, but are not limited to, citric acid, sodium citrate and the like and mixtures thereof. The method of packaging and storing a contact lens (or other ophthalmic device) comprises immersing the device in the compositions described above in a suitable container. The method may include immersing the device in the composition prior to delivery to the customer/wearer, directly following manufacture of the contact lens. Alternately, the incorporation and storing of the device in the compositions (all in the packaging) may occur at an intermediate point before delivery to the ultimate customer (wearer) but following manufacture and transportation of the device in a dry state, wherein the dry device is hydrated by immersing the device in the compositions. Consequently, a package for delivery to a customer may comprise a hermetically sealed container containing one or more unused devices (e.g., contact lenses) immersed in the compositions. The steps for packaging the ophthalmic device in the composition of the present invention may include: (1) molding an ophthalmic device (e.g., contact lens) in a mold comprising at least a first and second mold portion, (2) removing the device from the mold portions and removal of unreacted monomer and processing agents, (3) introducing the composition and the device into the packaging (or container), and (4) sealing the packaging. The method may also include the step of sterilizing the contents of the packaging. Sterilization may take place prior to, or most conveniently after, sealing of the container and may 26    Docket No. VTN6162WOPCT1 be performed by any suitable method known in the art, e.g., by autoclaving of the sealed container at temperatures of about 120° C. or higher (autoclave or steam sterilization method), or by using ultraviolet (UV) sterilization or gamma electron beam sterilization methods. Preferably, the compositions of the present invention are sterilized by autoclave sterilization. The packaging may be a plastic blister packaging (or package), including a recess for receiving an ophthalmic device and the composition, where the recess is hermetically sealed with lidstock prior to sterilization. The following examples are provided to enable one skilled in the art to practice the compositions and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention as defined in the claims. 27    Docket No. VTN6162WOPCT1 EXAMPLES The compositions of the present invention as described in following examples illustrate specific embodiments of compositions of the present invention but are not intended to be limiting thereof. Other modifications can be undertaken by the skilled artisan without departing from the spirit and scope of this invention. Examples 1-4 Table 1 shows the formulations for compositions having a range of chlorite concentrations useful as a solution for storing (or as packaging) solution for ophthalmic devices (e.g., contact lenses) or direct application eye drop solution, which composition was prepared using conventional mixing technology. Table 1 Component Vendor Weight % Ex 1 Ex 2 Ex 3 Ex 4 Sodium Phosphate, Spectrum 0.0904 0.0901 0.0902 0.0901 Monobasic, Monohydrate Dibasic Sodium Spectrum 0.7012 0.7006 0.6996 0.7001 Phosphate, Heptahydrate Sodium Chloride Fisher 0.5801 0.5805 0.5804 0.5807 EDTA Fisher 0.0751 0.0501 0.0251 0.0101 MEC Fisher 0.0050 0.0051 0.0051 0.0051 Deionized Water Internal 98.64 98.66 98.69 98.70 Once prepared, samples of each of the compositions of Examples 1-4 were poured from the original specimen cup containers and filter sterilized through a 0.22 μm membrane using a 150-mL Analytical Filter Unit. The filtered individual compositions were then aseptically transferred into new individual sterile specimen cups for storage and testing. The following microorganisms were used to assess microbial activity: ^ (AB) Aspergillus brasiliensis ((Quanti-Cult™)) - ATCC 16404 (Remel Inc.) ^ (BS) Bacillus subtilis – subspecies spizizenii (Epower ™) - ATCC 6633 (Microbiologics®) 28    Docket No. VTN6162WOPCT1 ^ (CA) Candida albicans (Epower ™) - ATCC 10231 (Microbiologics^®) The test microorganisms were resuspended following manufacturers’ instructions and approximately 0.5mL aliquots were spread plated onto two separate tryptic soy agar (TSA) media and Sabouraud dextrose agar (SDA) plates. The TSA and SDA plates were incubated at 30-35ºC and 20-25ºC respectively, for 2-7 days. Sterile filtered deionized (DI) water and inoculating loops were used to resuspend the designated test microorganisms from the plate surfaces and the suspensions were aseptically transferred with a sterile pipette into individual 50mL centrifuge tubes. The test microorganism suspensions were diluted until their population counts could be estimated using a hemocytometer. A population count of approximately 1.0 x 10⁷ cells/mL was targeted for each final test microorganism suspension. Depending on the test microorganism targeted suspension count, an aliquot ranging from 2.5 μL to 100 μL) was inoculated into 20mL of each of the samples of the test compositions of Table 3 to obtain an average starting microorganism population count of approximately 7000 CFU/mL. Each inoculated sample of the compositions of Table 11 containing the designated test microorganism was stored at room temperature and at Day 0, Day 1, Day 2, and Day 3 samples were pour-plated in duplicate (Day 0 only) or triplicate with either molten TSA or SDA containing chloramphenicol as required. The aliquot volumes were bracketed to increase the chances of the pour plate count results to be within the 25 CFU – 300 CFU countable range. All pour plate sample volumes were adjusted to 1mL using sterile water for injection (WFI) (i.e., 50μL + 950μL WFI) to allow for sufficient sample dispersion. AB was pour-plated with both TSA and SDA + chloramphenicol. When pour plated in parallel, the counts of A. brasiliensis were similar for the TSA and SDA+chloramphenicol. Consequently, TSA enabled the enumeration of A. brasiliensis on plates without interference due to sporulation. The results for microbial enumeration for Candida Albicans, Aspergillus brasiliensis and the bacteria Bacillus subtilis – subspecies spizizenii are shown in Table 2 below. 29    Docket No. VTN6162WOPCT1 CFU / mL Time C. albicans A. basiliensis B. spizenzzi ays Ex1 Ex2 Ex3 Ex4 Ex1 Ex2 Ex3 Ex4 Ex1 Ex2 Ex3 Ex4 0 11 13 13 17 66 101 51 171 188 178 171 196 8 0 0 1 0 110 108 10 101 349 170 163 170 14 0 0 0 0 94 98 16 124 217 163 137 149 20 0 0 0 0 104 82 32 155 172 173 130 143 The study results show inhibition of the growth of microorganisms across all concentrations above 0.01% evaluated, using only the chelant EDTA. For the yeast Candida albicans microbial counts dropped to 0 after 8 days at all EDTA concentrations evaluated. the fungus Aspergillus brasiliensis and the bacteria Bacillus subtilis – subspecies spizizenii, microbial counts showed slight to moderate decreases at the higher EDTA concentrations (0.05 and 0.075 wt%). The 0.025wt% EDTA showed no growth for Bacillus subtilis – subspecies spizizenii. The 0.025 wt% EDTA also showed no growth for Aspergillus brasiliensis (the slight increase reported in Table 2 is within detection limits). Examples 1-4 show that elevated concentration of EDTA, about 0.025 to about 0.075 wt% or about 0.005 to 0.075wt%, maintain or reduce microbial growth of the composition. It will be appreciated that the embodiments illustrated and described herein are among myriad embodiments within the scope of the invention as set forth in the appended claims. The foregoing description, for purposes of explanation, used specific nomenclature to provide a thorough understanding of the described embodiments, such that others can, by applying knowledge within the skill of the art, readily vary, modify and/or adapt for various applications such specific embodiments, without undue experimentation, and without departing from the general concept of the present invention. Such variations, modifications and adaptations are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. 30    Docket No. VTN6162WOPCT1 It will be apparent to one skilled in the art that many of the specific details may not be required to practice the described embodiments. Thus, the descriptions of the specific embodiments described herein are presented for the purposes of illustration. They are not targeted to be exhaustive or to limit the embodiments to the precise forms disclosed. The breadth and scope of the present invention should not be limited by any of the above- described embodiments but should be defined only in accordance with the following embodiments, claims and their equivalents. Embodiments of the Present Invention: 1. A sealed ophthalmologic product or kit, comprising: a) a composition for storing contact lenses as an admixture or mixture: i. a buffer; ii. about 0.02 to about 0.075 wt% chelant; and iii. an ophthalmologically acceptable carrier comprising one or more tonicity agents at least one contact lens sealed in a container with the composition and b) a container comprising a sealed compartment comprising at least one contact lens in the presence of the composition. 2. A method of inhibiting the growth of microorganisms in a composition for a period of time occurring from preparation of the composition to sterilization of the composition in sealed a container, comprising the steps of: a. mixing a composition comprising: iii. a buffer; and iv. about 0.02 to about 0.075 wt% chelant; b. storing the composition for the period of time during which time there is an inhibition of growth of microorganisms; c. placing the composition in a container; d. sealing the container of step c.; e. sterilizing the container of the d; 31    Docket No. VTN6162WOPCT1 optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. 3. A method of packaging and sterilizing a composition in sealed a container, comprising the steps of: mixing a composition comprising: i. a buffer; and ii. about 0.02 to about 0.075 wt% chelant; placing the composition in a container; sealing the container; sterilizing the sealed container; optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. 4. The product, kit or method or method of embodiments 1-3 wherein the composition is free from microbial growth inhibiting compounds. 5. The product, kit or method of embodiments 1-3 wherein the microbial growth inhibiting compounds are selected from chlorous acid compounds, peroxides and mixtures thereof. 6. The product, kit or method of embodiments 1-3 wherein the buffer is selected from phosphate compounds, organic acid buffers and mixtures thereof. 7. The product, kit or method of embodiment 6 wherein the buffer comprises at least one phosphate compound. 8. The product, kit or method of embodiment 7 wherein phosphate compound comprises a combination of salts of the dibasic phosphate anion (HPO₄)^2- and salts of the monobasic phosphate anion (H₂PO₄)-. 9. The product, kit or method of embodiment 7, wherein the phosphate compound is sodium dibasic phosphate (Na₂HPO₄), sodium monobasic phosphate (NaH₂PO₄) or a mixture thereof. Docket No. VTN6162WOPCT1 10. The product, kit or method of embodiments 7-9, wherein the phosphate compound buffer is present in the composition at concentrations of from about 0.3 wt% to about 0.9 wt%,  from about 0.4 wt% to about 0.85 wt%, from about 0.5 wt% to about 0.8 wt% or from about 0.6 wt% to about 0.75 wt% based on the total composition upon formulation. 11. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the chelant is selected from ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof, or mixtures thereof. 12. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the chelant comprises ethylenediaminetetraacetic acid (EDTA). 13. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition further comprises a demulcent polymer. 14. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the demulcent polymer is selected from block copolymer surfactants; polyvinyl alcohol, polyvinyl pyrrolidone; polyacrylic acid; polyethers; hyaluronic acid and hyaluronic acid derivatives; chitosan; polysorbates; dextrans; cellulosic derivatives; acyclic polyamides and mixtures thereof. 15. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the demulcent polymer is selected from polyvinyl pyrrolidone, methyl ethyl cellulose, polyvinyl alcohol, polymethacrylic acid, carboxymethyl cellulose, propylene glycol, 1,3-propanediol, polyethylene glycols, and mixtures thereof. 16. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the demulcent polymer is methyl ethyl cellulose. 17. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the demulcent polymer is a cellulosic derivative present at concentrations of from about 0.002% to about 0.01%, or from about 0.004% to about 0.006%, by weight of the total composition. 18. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the demulcent polymer is a water-soluble polymer present in amounts up to about 0.5, about 1 or about 2 weight %, or between about 0.001 and about 2%, between about 0.005 and about 1 weight %, between about 0.01 and about 0.5 Docket No. VTN6162WOPCT1 weight %, or between about 100 ppm by weight and about 0.5 weight %, all based upon the weight of total composition. 19. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition has an osmolality from about 200 mOsm/kg to less than about 500 mOsm/kg, from about 200 to about 450 mOsm/kg, from about 205 to about 380 mOsm/kg, from about 210 to about 360 (mOsm/kg), from about 250 to about 350 mOsm/kg, from about 270 to about 330 mOsm/kg, or about 205 mOsm/kg to about 350 mOsm/kg. 20. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition has a pH of from about 5.0 to a about 8.0, about 5.5 to about 8.0, about 6.0 to a about 8.0, from about 6.5 to about 8.0, or a pH of from about 6.5 to 7.5, or a pH of about 7.0 to about 7.5. 21. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition has a pH of from about 7.0 to about 7.5, or about 7.2 to about 7.4. 22. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition is free of boric acid and borates. 23. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition is manufactured under sterile conditions or sterilized during and/or after the period of time. 24. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition is sterilized after the period of time by a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization. 25. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. 26. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition is free of boric acid, borates, non-chlorous acid Docket No. VTN6162WOPCT1 preservatives, peroxides or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. 27. The product, kit or method of any of the preceding and succeeding embodiments, wherein the container further comprises an ophthalmic device. 28. The product, kit or method of embodiment 30, wherein the ophthalmic device is a contact lens. 29. The product, kit or method of embodiment 31, wherein the contact lens is a conventional hydrogel contact lens or a silicone hydrogel contact lens. 30. The product, kit or method of any of the preceding method embodiments and any succeeding method embodiments, wherein the composition is manufactured under sterile conditions or sterilized during and/or after the period of time. 31. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition is sterilized after the period of time by a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization. 32. The product, kit or method of any of the preceding method embodiments and any succeeding method embodiments, wherein the sterilization is by autoclave sterilization. 33. The product, kit or method of any of the preceding method embodiments and any succeeding method embodiments, wherein the contact lens further comprises a water- soluble polymer entrapped therein. 34. The product, kit or method of any of the preceding method embodiments and any succeeding method embodiments, wherein, prior to placing the composition in a container, the composition is stored for a period of time during which time there is inhibition of growth of microorganisms. 35. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition has a pH of from about 6.0 to a about 8.0, from about 6.5 to about 8.0, or a pH of from about 6.5 to 7.5, or a pH of about 7.0 to about 7.5. 36. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition has a pH of from about 7.0 to about 7.5, or about 7.2 to about 7.4. Docket No. VTN6162WOPCT1 37. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the composition is package or sterilized during and/or after the period of time. 38. The product, kit or method of any of the preceding embodiments and any succeeding embodiments, wherein the container is a plastic blister package, including a recess for receiving an ophthalmic device and the composition, where the recess is hermetically sealed with lidstock prior to sterilization. 39. The product, kit or method of any of the preceding or succeeding embodiments wherein the reductant comprises EDTA in a concentration of about 0.025 to about 0.075 wt% based upon the total composition upon formulation. 40. The product, kit or method of any of the preceding or succeeding embodiments wherein the hydrogel contact lens is silicone hydrogel contact lens. 41. The product, kit or method of any of the preceding embodiments and any succeeding embodiments wherein the contact lens is a hybrid contact lens. 42. The product, kit or method of any of the preceding embodiments and any succeeding embodiments wherein the buffer comprises a borate buffer. 43. The product, kit or method of any of the preceding embodiments and any succeeding embodiments wherein the buffer comprises at least one organic acid buffer. 44. The product, kit or method of embodiment 43 wherein the organic acid buffer is a non- phosphate containing organic acid having two or more carboxylic acid groups. 45. The composition of embodiments 43-44 wherein the organic acid buffer is selected from phytic acid, mellitic acid, maleic acid and ophthalmically compatible salts thereof. 46. The composition of embodiments 43-45, wherein the organic acid buffer is selected from mellitic acid, maleic acid and salts thereof and mixtures thereof. 47. The composition of embodiments 43-46, wherein the organic acid buffer is maleic acid, salts thereof and mixtures thereof. 48. The composition of embodiments 43-47 wherein the organic acid buffer is selected from maleic acid, its sodium or potassium salts and mixtures thereof. 49. The composition of embodiments 43-48 wherein the organic acid buffer is selected from mellitic acid, its sodium or potassium salts and mixtures thereof. Docket No. VTN6162WOPCT1 50. The composition of embodiments 43-49 wherein the organic acid buffer comprises salts of dibasic organic acid anion (e.g., dibasic sodium maleate monohydrate) and salts of monobasic organic acid anion (monobasic sodium maleate). 51. The composition of embodiments 43-50 wherein prior to sterilization of the composition the concentration, of the dibasic organic acid anion is from about 0.1% to about 0.3% and the concentration of the monobasic organic acid anion is from 0.005% to about 0.002%, by weight of the composition, when present as the metal (e.g., sodium) monohydrate in the case of the dibasic organic acid. 52. The composition of any of the preceding embodiments and any succeeding embodiments, wherein the composition is free of boric acid and borates. 53. The composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer is a non-phosphate containing organic acid having two or more carboxylic acid groups. 54. The composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer is selected from phytic acid, mellitic acid, maleic acid and ophthalmically compatible salts thereof. 55. The composition of any of the preceding embodiments and any succeeding embodiments, wherein the organic acid buffer is selected from mellitic acid, maleic acid and salts thereof and mixtures thereof. 56. The composition of any of the preceding embodiments and any succeeding embodiments, wherein the organic acid buffer is maleic acid, salts thereof and mixtures thereof. 57. The composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer is selected from maleic acid, its sodium or potassium salts and mixtures thereof. 58. The composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer is selected from mellitic acid, its sodium or potassium salts and mixtures thereof. 59. The composition of any of the preceding embodiments and any succeeding embodiments wherein the organic acid buffer comprises salts of dibasic organic acid anion (e.g., dibasic sodium maleate monohydrate) and salts of monobasic organic acid anion (monobasic sodium maleate). Docket No. VTN6162WOPCT1 The composition of any of the preceding embodiments and any succeeding embodiments wherein prior to sterilization of the composition the concentration, of the dibasic organic acid anion is from about 0.1% to about 0.3% and the concentration of the monobasic organic acid anion is from 0.005% to about 0.002%, by weight of the composition, when present as the metal (e.g., sodium) monohydrate in the case of the dibasic organic acid.

Claims

Docket No. VTN6162WOPCT1 What is claimed is: 1. A sealed ophthalmologic product or kit, comprising: a) a composition for storing contact lenses as an admixture or mixture: i. a buffer; ii. about 0.02 to about 0.075 wt% at least one chelant, based upon the total weight of the composition upon formulation; and iii. an ophthalmologically acceptable carrier comprising one or more tonicity agents at least one contact lens sealed in a container with the composition; and b) wherein the container comprises a sealed compartment comprising the at least one contact lens in the presence of the composition. 2. The product or kit of claim 1, wherein the chelant is selected from ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof, or mixtures thereof. 3. The product or kit of claim 1, wherein chelant comprises ethylenediaminetetraacetic acid (EDTA). 4. The product or kit of claim 3, wherein the composition is free from microbial growth inhibiting compounds. 5. The product or kit of claim 1, wherein the buffer comprises at least one phosphate compound comprising a combination of salts of the dibasic phosphate anion (HPO₄)^2- and salts of the monobasic phosphate anion (H2PO4)-. 6. The product or kit of claim 1, wherein the buffer comprises at least one phosphate compound is present in the composition at concentrations of from about 0.3 wt% to about 0.9 wt% based on the total composition. 7. The product or kit of claim 4, wherein the microbial growth inhibiting compounds are selected from chlorous acid compounds, peroxides and mixtures thereof. 8. The product or kit of claim 3 wherein EDTA is present in a concentration of about 0.025 to about 0.075 wt% based upon the total composition upon formulation. 9. The product or kit of claim 1, wherein the composition further comprises a demulcent polymer. 39    Docket No. VTN6162WOPCT1 10. The product or kit of claim 9, wherein the demulcent polymer is selected from block copolymer surfactants; polyvinyl alcohol, polyvinyl pyrrolidone; polyacrylic acid; polyethers; hyaluronic acid and hyaluronic acid derivatives; chitosan; polysorbates; dextrans; cellulosic derivatives; acyclic polyamides and mixtures thereof. 11. The product or kit of claim 10, wherein the demulcent polymer is selected from polyvinyl pyrrolidone, methyl ethyl cellulose, polyvinyl alcohol, polymethacrylic acid, carboxymethyl cellulose, propylene glycol, 1,3-propanediol, polyethylene glycols, and mixtures thereof. 12. The product or kit of claim 11, wherein the demulcent polymer is methyl ethyl cellulose. 13. The product or kit of claim 1 wherein the osmolality is from about 200 mOsm/kg to less than about 450 mOsm/kg. 14. The product or kit of claim 1 wherein the composition is manufactured under sterile conditions or sterilized during and/or after the period of time. 15. The product or kit of claim 1 wherein the composition is sterilized after the period of time by a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization. 16. The product or kit of claim 1 wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. 17. The product or kit of claim 20, wherein the composition is free of boric acid, borates, non-chlorous acid preservatives, peroxides or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. 18. The product or kit of any of the forgoing claims wherein the ophthalmic device is a silicone hydrogel contact lens. 19. The product or kit of claim 7 wherein the chelant comprises EDTA in a concentration of about 0.05 to about 0.075 wt% based upon the total composition upon formulation. 20. The product or kit of claim 18 wherein the chelant comprises EDTA in a concentration of about 0.05 to about 0.075 wt% based upon the total composition upon formulation. 21. The product or kit of claim 1 wherein the product is sterilized via autoclave sterilization. Docket No. VTN6162WOPCT1 22. A method of inhibiting the growth of microorganisms in a composition for a period of time occurring from preparation of the composition to sterilization of the composition sealed in a container, comprising the steps of: a. mixing a composition comprising: i. a phosphate compound; and ii. a chelant in an amount effective to inhibit the growth of microorganisms in the composition; b. storing the composition for the period of time during which time there is an inhibition of growth of microorganisms; c. placing the composition in a container; d. sealing the container of step c.; e. sterilizing the container of the d; optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. 23. The method of claim 21, wherein the container further comprises an ophthalmic device. 24. The method of claim 22, wherein the ophthalmic device is a contact lens. 25. The method of claim 23, wherein the contact lens is a conventional hydrogel contact lens or a silicone hydrogel contact lens. 26. The method claim 24, wherein the chelant is selected from ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof, or mixtures thereof 27. The method of claim 24, wherein chelant comprises ethylenediaminetetraacetic acid (EDTA). 28. The method of claim 24 wherein the chelant comprises EDTA in a concentration of about 0.025 to about 0.075 wt% based upon the total composition upon formulation 29. The method of claim 21, wherein the sterilization is selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization. 30. The method of claim 21, wherein the sterilization is by autoclave sterilization. 31. The method of claim 21, wherein the container contains at least one contact lens. Docket No. VTN6162WOPCT1 32. The method of claim 21, wherein the contact lens comprises a polymeric material selected from conventional hydrogel polymers or silicone hydrogel polymers. 33. A method of packaging and sterilizing a composition in sealed a container, comprising the steps of: a. mixing a composition comprising: i. a phosphate compound; and ii. a chelant in an amount effective to inhibit the growth of microorganisms in the composition; b. placing the composition in a container; c. sealing the container of step b.; d. sterilizing the container of the c. optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof. 34. The method of claim 33, wherein the container contains at least one contact lens. 35. The method of claim 34, wherein the contact lens comprises a polymeric material selected from conventional hydrogel polymers or silicone hydrogel polymers. 36. The method of claim 34, wherein the composition and contact lens are hermetically sealed in the container. 37. The method of claim 34, wherein the sterilization is by autoclave sterilization. 38. The method of claim 34 wherein the EDTA is present in a concentration of about 0.025 wt% to about 0.075 wt% based upon the total composition upon formulation. 39. The product or kit of claim 1 wherein the acid comprises an organic acid buffer comprises at least one non-phosphate containing organic acid having two or more carboxylic acid groups. 40. The product or kit of claim 39 wherein the organic acid buffer is selected from phytic acid, mellitic acid, maleic acid and ophthalmically compatible salts thereof. 41. The composition of claim 39 wherein the organic acid buffer is selected from mellitic acid, maleic acid and salts thereof and mixtures thereof. Docket No. VTN6162WOPCT1 42. The composition of claim 39, wherein the organic acid buffer is maleic acid, salts thereof and mixtures thereof. 43. The composition of claim 39 wherein the organic acid buffer comprises salts of dibasic organic acid anion (e.g., dibasic sodium maleate monohydrate) and salts of monobasic organic acid anion (monobasic sodium maleate). 44. The composition of claims 39-43 wherein prior to sterilization of the composition the concentration, of the dibasic organic acid anion is from about 0.1% to about 0.3% and the concentration of the monobasic organic acid anion is from 0.005% to about 0.002%, by weight of the composition, when present as the metal (e.g., sodium) monohydrate in the case of the dibasic organic acid.